Table 3.
Patient and irAE outcomes according to bDMARD/tsDMARD type
| bDMARD/ tsDMARD | Type of cancer | Type of irAE | DMARD duration (median, weeks) | Association with ICI | Safety | Efficacy | Cancer outcomes |
| Anti-IL-6R | Lung (n=6) Melanoma (n=6) Renal (n=1) |
RA-like (n=10) | 17 (6 ongoing) | Yes (n=3) | 0 | Partial improvement (n=3) | Progression (n=2) Stable (n=1) |
| PMR-like (n=2) | No (10) | Small intestine perforation (n=1) Septic shock (n=1) (ongoing chemotherapy) |
Resolution (n=3) Partial improvement (n=5) No efficacy (n=2) |
Progression (n=4) Stable (n=2) Partial response (n=1) Remission (n=3) |
|||
| PsA-like (n=1) | |||||||
| TNF inhibitors | Lung (n=4) Lymphoma (n=1) |
RA-like (n=5) | 8 (2 ongoing) | Yes (n=3) | Diverticulitis (n=1) Pneumonitis (n=1) |
Resolution (n=1) Partial improvement (n=1) No efficacy (n=1) |
Progression (n=3) |
| No (n=2) | 0 | Resolution (n=2) | Remission (n=2) | ||||
| Anakinra | Melanoma | RA-like (n=1) | 1 | Yes | 0 | No efficacy | Stable |
| Baricitinib | Lung | RA-like (n=1) | 78 (ongoing) | No | 0 | Resolution | Progression |
| Ustekinumab | Lung | PsA-like (n=1) | 60 (ongoing) | Yes | 0 | Partial improvement | Stable |
bDMARD, biologic disease-modifying antirheumatic drug; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.